Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-r... von Rathkopf, D.E., Patel, M.R., Choudhury, A.D., Rasco, D., Lakhani, N., Hawley, J.E., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K.D., Emamekhoo, H., Reichert, Z.R., Nguyen, M.H., Wells, A.L., Kandimalla, R., Liu, C., Suryawanshi, S., Han, J., Wu, J., Arora, V.K., Pourdehnad, M., Armstrong, A.J.

Volltext

1415P Phase II trial of a DNA vaccine with nivolumab in patients with PSA-recurrent, castration-sensitive prostate cancer (nmCSPC) von McNeel, D.G., Emamekhoo, H., Eickhoff, J., Wargowski, E., Liu, G.

Volltext

1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study von Kilari, D., Szabo, A., Bilen, M.A., Ged, Y., Maughan, B.L., Hwang, C., McManus, H., Coelho Barata, P.M., Desai, A., Zakharia, Y., Emamekhoo, H., Tripathi, A., Rose, T., Ghatalia, P., Reimers, M.A., Heath, E., King, J.M., Rini, B.I., Brugarolas, J., McKay, R.R.

Volltext

1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC)... von Lang, J.M., Tagawa, S.T., Slovin, S., Sperger, J.M., Schehr, J.L., Stahlfeld, C., Hintz, A.M., Emamekhoo, H., Rathkopf, D., Abida, W., Autio, K., Xiao, H., Mitchell, A., Molina, A.M., Zhao, S.G., Eickhoff, J., Dehm, S., Nanus, D.M., Kyriakopoulos, C.

Volltext

1597MO Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castr... von Rathkopf, D., Patel, M.R., Choudhury, A.D., Rasco, D., Lakhani, N.J., Hawley, J., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K., Emamekhoo, H., Reichert, Z., Nguyen, H., Wells, A., Kandimalla, R., Suryawanshi, S., Wu, J., Arora, V., Pourdehnad, M., Armstrong, A.J.

Volltext

1989P Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE stu... von Jang, A., Jindal, T., Jiang, C.Y., Nguyen, C.B., Nizam, A., Alva, A.S., Grivas, P., Bellmunt, J., Hoimes, C.J., Bilen, M.A., Emamekhoo, H., Milowsky, M.I., Khaki, A.R., Gupta, S., Campbell, M.T., Alhalabi, O., Chen, Z., Fu, P., Koshkin, V.S., Brown, J.R.

Volltext

1972P Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE von Nizam, A., Zhang, L., Jiang, C.Y., Nguyen, C.B., Bakaloudi, D.R., Bilen, M.A., Coelho Barata, P.M., Zakharia, Y., Milowsky, M.I., Kilari, D., Hoimes, C.J., Khaki, A.R., Emamekhoo, H., Gupta, S., Grivas, P., Bellmunt, J., Alva, A.S., Campbell, M.T., Alhalabi, O., Koshkin, V.S.

Volltext

1646P A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive... von Wei, X.X., Chahoud, J., Emamekhoo, H., McKay, R.R., Marshall, C.H., Einstein, D., Lang, J.M., Raymond, S., Roberts, D.A., Ravi, P., Tewari, A., Pomerantz, M., Dong, F., Siegmund, S., Rodig, S., Sweeney, C., Taplin, M.E.

Volltext

1406P Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen recep... von Lang, J., Tagawa, S.T., Slovin, S., Emamekhoo, H., Rathkopf, D., Abida, W., Autio, K., Xiao, H., Molina, A.M., Eickhoff, J., Sperger, J.M., Dehm, S., Nanus, D.M., Kyriakopoulos, C.E.

Volltext

2394P Biomarkers of treatment (Tx)-related toxicity in advanced urothelial carcinoma (aUC) pts treated with enfortumab vedotin (EV): Analysis of UNITE study von Nizam, A., Zhang, L., Jindal, T., Nguyen, C.B., Alhalabi, O., Basu, A., Evans, S.P., Hoimes, C.J., Zakharia, Y., Milowsky, M.I., Kilari, D., Shah, S.A., Davis, N.B., Emamekhoo, H., Gupta, S., Bellmunt, J., Grivas, P., Campbell, M.T., Alva, A., Koshkin, V.S.

Volltext

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels von Helzer, K.T., Sharifi, M.N., Sperger, J.M., Shi, Y., Annala, M., Bootsma, M.L., Reese, S.R., Taylor, A., Kaufmann, K.R., Krause, H.K., Schehr, J.L., Sethakorn, N., Kosoff, D., Kyriakopoulos, C., Burkard, M.E., Rydzewski, N.R., Yu, M., Harari, P.M., Bassetti, M., Blitzer, G., Floberg, J., Sjöström, M., Quigley, D.A., Dehm, S.M., Armstrong, A.J., Beltran, H., McKay, R.R., Feng, F.Y., O’Regan, R., Wisinski, K.B., Emamekhoo, H., Wyatt, A.W., Lang, J.M., Zhao, S.G.

Volltext

LBA54ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell c... von Motzer, R J, Lee, C-H, Emamekhoo, H, Matrana, M, Percent, I, Hsieh, J J, Hussain, A, Vaishampayan, U N, Graham, R, Liu, S, McCune, S, Shaheen, M, Parmar, H, Shen, Y, Whiting, S H, Tannir, N M

Volltext

ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcin... von Motzer, R.J., Lee, C.-H., Emamekhoo, H., Matrana, M., Percent, I., Hsieh, J.J., Hussain, A., Vaishampayan, U.N., Graham, R., Liu, S., McCune, S., Shaheen, M., Parmar, H., Shen, Y., Whiting, S.H., Tannir, N.M.

Volltext

LBA54 - ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cel... von Motzer, R.J., Lee, C.-H., Emamekhoo, H., Matrana, M., Percent, I., Hsieh, J.J., Hussain, A., Vaishampayan, U.N., Graham, R., Liu, S., McCune, S., Shaheen, M., Parmar, H., Shen, Y., Whiting, S.H., Tannir, N.M.

Volltext

8P Factors associated with primary progression in patients with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV): Analysis of the UNITE study von Jindal, T., Jiang, C., Alhalabi, O., Nguyen, C.B., Nizam, A., Basu, A., Zakharia, Y., Bilen, M.A., Brown, J., Milowsky, M., Kilari, D., Emamekhoo, H., Hoimes, C.J., Shah, S., Gupta, S., Grivas, P., Bellmunt, J., Campbell, M.T., Alva, A., Koshkin, V.S.

Volltext

Sequence-Specific Correction of Genomic Hypoxanthine-Guanine Phosphoribosyl Transferase Mutations in Lymphoblasts by Small Fragment Homologous Replacement von Bedayat, Babak, Abdolmohamadi, Alireza, Ye, Lin, Maurisse, Rosalie, Parsi, Hooman, Schwarz, Jennifer, Emamekhoo, Hamid, Nicklas, Janice A., O'Neill, J. Patrick, Gruenert, Dieter C.

Volltext

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma von Tzeng, Alice, Diaz-Montero, C. Marcela, Rayman, Patricia A., Kim, Jin S., Pavicic, Paul G., Finke, James H., Barata, Pedro C., Lamenza, Marcelo, Devonshire, Sarah, Schach, Kim, Emamekhoo, Hamid, Ernstoff, Marc S., Hoimes, Christopher J., Rini, Brian I., Garcia, Jorge A., Gilligan, Timothy D., Ornstein, Moshe C., Grivas, Petros

Volltext

Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study von Allaf, Mohamad E, Kim, Se-Eun, Master, Viraj, McDermott, David F, Harshman, Lauren C, Cole, Suzanne M, Drake, Charles G, Signoretti, Sabina, Akgul, Mahmut, Baniak, Nicholas, Li-Ning, Elsa, Palmer, Matthew B, Emamekhoo, Hamid, Adra, Nabil, Kaimakliotis, Hristos, Ged, Yasser, Pierorazio, Phillip M, Abel, E Jason, Bilen, Mehmet A, Ogan, Kenneth, Moon, Helen H, Ramaswamy, Krishna A, Singer, Eric A, Mayer, Tina M, Lohrey, Jay, Margulis, Vitaly, Gills, Jessie, Delacroix, Scott E, Waples, Mark J, James, Andrew C, Wang, Peng, Choueiri, Toni, Michaelson, M Dror, Kapoor, Anil, Heng, Daniel Y, Shuch, Brian, Leibovich, Bradley C, Lara, Primo N, Manola, Judith, Maskens, Deborah, Battle, Dena, Uzzo, Robert, Bratslavsky, Gennady, Haas, Naomi B, Carducci, Michael A

Volltext

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cyste... von Ornstein, Moshe C., Diaz-Montero, Claudia Marcela, Rayman, Patricia, Elson, Paul, Haywood, Samuel, Finke, James H., Kim, Jin S., Pavicic, Paul G., Lamenza, Marcelo, Devonshire, Sarah, Dann, Priscilla, Schach, Kim, Stephenson, Andrew, Campbell, Steven, Emamekhoo, Hamid, Ernstoff, Marc S., Hoimes, Christopher J., Gilligan, Timothy D., Rini, Brian I., Garcia, Jorge A., Grivas, Petros

Volltext

Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter Analysis von Hakimi, Kevin, Saidian, Ava, Panian, Justine, Barata, Pedro, Berg, Stephanie, Chang, Steven L, Saliby, Renee M, Dzimitrowicz, Hannah, Emamekhoo, Hamid, Gross, Evan, Kilari, Deepak, Lam, Elaine, Nguyen, Mimi, Meagher, Margaret, Wang, Luke, Rauterkus, Grant P, D'Andrea, Vincent, Yim, Kendrick, Psutka, Sarah, Thapa, Bicky, Weise, Nicole, Zhang, Tian, McKay, Rana R, Derweesh, Ithaar H

Volltext